Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

NORTH Trial: A phase II study of Panobinostat in Paediatric, Adolescent and Young Adults with Solid Tumours including Neuroblastoma, Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours

Solid Tumours: Malignant Rhabdoid Tumour, Atypical Teratoid Rhabdoid Tumour, Neuroblastoma, Osteoscaroma

The purpose of the study is to determine the ability of the drug panobinstat to control the growth of each of the tumour types and to describe the drug’s side effects. The drug is taken orally every day for up to 12 months. The effectiveness of the drug is measured through regular follow ups, including medical imaging.

NORTH is also open at The Preston Robert Tisch Brain Tumor Center at Duke in Durham, North Carolina.

Disease Stage: Relapsed/refractory and limited newly diagnosed

Patient Age Range: <40 years of age

Sample Size: 60

Trial Sponsors:

  • National: ANZCHOG in partnership with ANZSA

Read more at the Clinical Trial Registry

ANZCHOG acknowledges the valuable support of the NORTH trial by the Australian Government through the NHMRC Program Grant scheme, Novartis Pharmaceuticals Australia and The Kids’ Cancer Project.